Kristina Lybecker

Professor of Economics @ColoradoCollege fields of expertise: IP, innovation, global health, pharmaceutical policy, neglected diseases

[Kristina Lybecker @DrLybecker]

Don’t overlook stronger IP as a tool to improve access to innovative treatments. https://t.co/TNODGhXrao #fairpricingforum

[Kristina Lybecker @DrLybecker]

.@WHO Fair Pricing Forum too narrowly focused on price setting to improve access. https://t.co/TNODGhXrao #fairpricingforum

[Kristina Lybecker @DrLybecker]

The UN High Level Panel on Innovation and Access. Are they ignoring the real barriers to access to medicines? https://t.co/uD30S5VXO1

[Kristina Lybecker @DrLybecker]

My post in IP Watchdog: http://t.co/8quHjQPzXe

[Patrick Kilbride @pjkilbride]

For public health, Australia should protect biologics with both robust patents and RDP - http://t.co/V5wKrKe4TA by @DrLybecker @PhRMA

[EFPIA @EFPIA]

Why is #TTIP important to the pharmaceutical industry? http://t.co/aH48XX9Xmj #TTIPqa

[Kristina Lybecker @DrLybecker]

Nat'l governments determine pricing and reimbursement of medicines. This won't change under the TTIP http://t.co/g4ySkLRzFo #TTIPqa

[Kristina Lybecker @DrLybecker]

Increased efficiency can generate cost savings and translate into greater investment in the search for cures #TTIPqa http://t.co/82QePdGtUJ

[Kristina Lybecker @DrLybecker]

TTIP will harmonize of regulatory systems enabling quicker patient access to new treatments and cures #TTIPqa http://t.co/82QePdGtUJ

[Kristina Lybecker @DrLybecker]

TTIP will generate research cooperation, foster sharing of knowledge, and speed the launch of new treatments #TTIPqa http://t.co/tWu0Gd9K9H

[Mark Grayson @MarkGinDC]

.@DrLybecker: IP-intensive industries have double the sales & capital spending than non-IP-intensive industries http://t.co/qZVxpKvzl1

[Kristina Lybecker @DrLybecker]

Looking forward to discussing this Friday how the EU-US trade agreement impacts patients and industry #TTIPqa

[Kristina Lybecker @DrLybecker]

IP Protection is Key to U.S. Job Creation via http://t.co/VmxTedbpfQ

[Kristina Lybecker @DrLybecker]

#TPP can eliminate protectionist tariffs that raise the prices of medicines for the poorest and weakest. #TPPQA http://t.co/lNjXcuPSwk

[Eli Lilly and Company @EliLillyandCo]

.@DrLybecker explains how undermining the data exclusivity provisions in #TPP threatens the future of #biologics. http://t.co/Yo53lL3g7O

[Eli Lilly and Company @EliLillyandCo]

Is the future of the most promising medical frontier under attack? @DrLybecker weighs in: http://t.co/Yo53lL3g7O

[Kristina Lybecker @DrLybecker]

Nothing in #TPP stops medicines that have exhausted their patent lives from becoming available as generics #TPPQA http://t.co/eaS0qbuEGi

[Kristina Lybecker @DrLybecker]

My guest blog @Lillypad "Protect the Incentives for Hope, Treatment & Cures" http://t.co/YYdc2fFXi5

[Kristina Lybecker @DrLybecker]

#FHQA Better awareness, screening, medicines can all reduce the global burden of familial hypercholesterolemia (FH) http://t.co/fAcTejdgHV

[Kristina Lybecker @DrLybecker]

The therapeutic and economic value of incremental pharmaceutical innovation. http://t.co/fql0Xs460l